Endovascular Cardiac Valve Replacement DRG 266 Reimbursement

DRG 266 captures inpatient stays for endovascular cardiac valve replacement and supplement procedures when a Major Complication or Comorbidity is present, reflecting higher clinical complexity. Correct grouping to this Diagnosis-Related Group affects Medicare inpatient reimbursement because it elevates payment relative to less-severe valve procedure groupings.

DRG 266 Overview

DRG 266 covers inpatient admissions for endovascular cardiac valve replacement and related supplement procedures when a Major Complication or Comorbidity is present. This Diagnosis-Related Group applies to patients undergoing transcatheter or other endovascular valve interventions who require additional care complexity due to significant comorbid conditions or in-hospital complications. It matters for Medicare payment because the presence of a Major Complication or Comorbidity increases resource use and drives higher relative reimbursement compared with similar procedures without such severity. Accurate coding of the valve procedure and Major Complication or Comorbidity is critical to ensure the claim maps to this Diagnosis-Related Group.

Acute procedural safety and efficacy trials of transcatheter aortic or mitral valve replacement in high-risk inpatients: These studies evaluate procedural techniques, peri-procedural management, and immediate in-hospital outcomes for patients undergoing endovascular cardiac valve replacement who have major comorbidities or complications (the MCC population). They focus on procedural success, in-hospital mortality, bleeding, vascular complications, and length of stay, providing data that inform acute care pathways and resource use for clinicians and payers managing high-acuity admissions under this DRG.
Comparative effectiveness research on valve replacement approaches and adjunct procedures in complex patients: Trials and prospective registries compare different endovascular valve devices, access strategies (e.g., transfemoral versus alternative access), and use of supplement procedures (such as concomitant coronary or structural interventions) in patients with multiple comorbid conditions. These studies target decision-making for which approach optimizes clinical outcomes and reduces complications and readmissions, directly impacting case mix, expected costs, and reimbursement considerations for providers and payers.
Post-discharge outcomes and care-transition studies focused on readmissions, rehabilitation, and long-term functional status after endovascular valve replacement with complications: This research follows patients after hospital discharge to assess rates and drivers of 30- and 90-day readmission, durable symptom relief, valve function, and needs for post-acute care services among those who had major complications during the index admission. Findings help inform discharge planning, bundled payment models, and strategies to reduce costly readmissions and downstream utilization for the high-risk cohort captured by this DRG.

Acute procedural safety and efficacy trials of transcatheter aortic or mitral valve replacement in high-risk inpatients: These studies evaluate procedural techniques, peri-procedural management, and immediate in-hospital outcomes for patients undergoing endovascular cardiac valve replacement who have major comorbidities or complications (the MCC population). They focus on procedural success, in-hospital mortality, bleeding, vascular complications, and length of stay, providing data that inform acute care pathways and resource use for clinicians and payers managing high-acuity admissions under this DRG.
Comparative effectiveness research on valve replacement approaches and adjunct procedures in complex patients: Trials and prospective registries compare different endovascular valve devices, access strategies (e.g., transfemoral versus alternative access), and use of supplement procedures (such as concomitant coronary or structural interventions) in patients with multiple comorbid conditions. These studies target decision-making for which approach optimizes clinical outcomes and reduces complications and readmissions, directly impacting case mix, expected costs, and reimbursement considerations for providers and payers.
Post-discharge outcomes and care-transition studies focused on readmissions, rehabilitation, and long-term functional status after endovascular valve replacement with complications: This research follows patients after hospital discharge to assess rates and drivers of 30- and 90-day readmission, durable symptom relief, valve function, and needs for post-acute care services among those who had major complications during the index admission. Findings help inform discharge planning, bundled payment models, and strategies to reduce costly readmissions and downstream utilization for the high-risk cohort captured by this DRG.

OpenPayer

Summary & Overview

Endovascular Cardiac Valve Replacement and Supplement Procedures with MCC: Inpatient Reimbursement Overview

DRG 266 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes